NAFLD and COVID-19: a Pooled Analysis

被引：63
作者：
Sonali Sachdeva
Harshwardhan Khandait
Jonathan Kopel
Mark M. Aloysius
Rupak Desai
Hemant Goyal
机构：
[1] Lady Hardinge Medical College,Department of Medicine
[2] Government Medical College,Department of Medicine
[3] Texas Tech University Health Sciences Center,Department of Medicine
[4] The Wright Center for Graduate Medical Education,Division of Cardiology
[5] Atlanta VA Medical Center,undefined
来源：
SN Comprehensive Clinical Medicine | 2020年 / 2卷 / 12期
关键词：
SARS-CoV-2; COVID-19; Coronavirus; NAFLD; MAFLD; Fatty liver;
D O I：
10.1007/s42399-020-00631-3
中图分类号：
学科分类号：
摘要：
The earliest evidence from China suggested that COVID-19 patients are even more vulnerable to succumbing from complications in the presence of a multimorbid status, including metabolic syndrome. Due to ongoing metabolic abnormalities, non-alcoholic fatty liver disease (NAFLD) appears to be a potential risk factor for contracting SARS-CoV-2 infection and developing related complications. This is because of the interplay of chronically active inflammatory pathways in NAFLD- and COVID-19-associated acute cytokine storm. The risk of severe disease could also be attributed to compromised liver function as a result of NAFLD. We systematically reviewed current literature to ascertain the relationship between NAFLD and severe COVID-19, independent of obesity, which is considered the major factor risk factor for both NAFLD and COVID-19. We found that NAFLD is a predictor of severe COVID-19, even after adjusting for the presence of obesity (OR 2.358; 95% CI: 1.902–2.923, p < 0.001).
引用
收藏
页码：2726 / 2729
页数：3
相关论文
共 76 条
[1]  
Boregowda U(2020)Serum activity of liver enzymes is associated with higher mortality in COVID-19: a systematic review and meta-analysis Front Med (Lausanne) 7 431-2754
[2]  
Aloysius MM(2020)Higher frequency of hepatic steatosis at CT among COVID-19-positive patients Abdom Radiol (NY) 45 2748-1547
[3]  
Perisetti A(2020)Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores Gut. 69 1545-721
[4]  
Gajendran M(2020)Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis J Hepatol 73 719-2163
[5]  
Bansal P(2020)Metabolic-associated fatty liver disease is associated with severity of COVID-19 Liver Int 40 2160-453
[6]  
Goyal H(2020)Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study J Hepatol 73 451-66
[7]  
Medeiros AK(2017)Liver — guardian, modifier and target of sepsis Nat Rev Gastroenterol Hepatol 14 55-300
[8]  
Barbisan CC(2020)Obesity and mortality of COVID-19. Meta-analysis Obes Res Clin Pract 14 295-70
[9]  
Cruz IR(2013)Characteristics and diagnosis of NAFLD/NASH J Gastroenterol Hepatol 28 64-undefined
[10]  
de Araújo EM(2020)Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease Metabolism 108 154244-undefined
12345678